Followers | 0 |
Posts | 1521 |
Boards Moderated | 0 |
Alias Born | 09/16/2005 |
Tuesday, July 25, 2017 3:49:42 PM
Thank you for your enquiry of 24 June 2017 regarding the number of medicines that have received a positive opinion from CHMP but then failed to obtain a marketing authorisation.
Please note that currently no medicine has obtained a positive CHMP recommendation and was then subsequently refused marketing authorisation.
However, a number of marketing authorisation applications have actually been withdrawn after the CHMP issued a positive recommendation and before the European Commission could make a decision on the marketing authorisation:
Desloratadine Krka (desloratadine)
Egranli (balugrastim)
Folcepri (etarfolatide)
Ibandronic Acid Hexal (ibandronic acid)
Lunivia (eszopiclone)
Neocepri (folic acid)
Pioglitazone ratio (pioglitazone)
Pioglitazone ratiopharm (pioglitazone)
Pioglitazone ratiopharm GmbH (pioglitazone)
Pioglitazone Teva Generics (pioglitazone)
ratioepo (epoetin theta)
Vynfinit (vintafolide)
Desloratadine Krka (desloratadine)
Egranli (balugrastim)
We hope you find this information helpful. We would be grateful if you could take part in a short survey on our service, which you can access through the following link:
https://ec.europa.eu/eusurvey/runner/AskEMA
With kind regards,
Inga Abed
European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM